IBT
CHRS icon

International Biotechnology Trust’s Coherus Oncology CHRS Stock Holding History

International Biotechnology Trust’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-62,000
Closed -$1.31M – 63
2017
Q1 		$1.31M Buy
+62,000
New +$1.53M 0.5% 40

Other funds holding CHRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

International Biotechnology Trust's CHRS Position: Q2 2017 in Review

International Biotechnology Trust sold out of Coherus Oncology (CHRS) in Q2 2017, closing a stake of 62,000 shares — an estimated $1.31M sold.

International Biotechnology Trust first reported a position in CHRS in Q1 2017 and held it in 1 quarter. The position peaked at $1.31M in Q1 2017. 106 funds tracked by Wall St. Rank hold CHRS as of Q2 2017.

  • International Biotechnology Trust reported no remaining Coherus Oncology position as of Q2 2017 after selling out during the quarter.
  • International Biotechnology Trust sold 62,000 Coherus Oncology shares in Q2 2017, an estimated $1.31M.
  • International Biotechnology Trust first reported a position in Coherus Oncology in Q1 2017 and held it in 1 quarter.
  • International Biotechnology Trust's Coherus Oncology position peaked at $1.31M in Q1 2017.
  • 106 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2017.

Based on International Biotechnology Trust's 13F filing for Q2 2017, filed 2 Mar 2018.